Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor
US-2015164897-A1 · Jun 18, 2015 · US
Pharmaceutical combination comprising binimetinib
US9867825B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9867825-B2 |
| Application number | US-201314651297-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2013 |
| Priority date | Dec 20, 2012 |
| Publication date | Jan 16, 2018 |
| Grant date | Jan 16, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A combination comprising (a) a first agent Compound A of Formula A or a pharmaceutically acceptable salt thereof and (b) a second agent Compound B of Formula B or a pharmaceutically acceptable salt thereof. 2. The combination of claim 1 further comprising one or more excipients. 3. The combination of claim 1 wherein the first agent is the succinate salt of Compound A. 4. The combination of claim 1 wherein Compound A and Compound B are administered simultaneously. 5. The combination of claim 1 wherein Compound A and Compound B are administered separately. 6. The combination of claim 1 wherein Compound A and Compound B are administered sequentially. 7. A method of treating cancer comprising administer to a subject in need of such treatment (a) a first agent Compound A of Formula A or a pharmaceutically acceptable salt thereof and (b) a second agent Compound B of Formula B or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 , wherein the cancer is a solid tumor cancer. 9. The method of claim 8 , wherein the cancer is pancreatic cancer, breast cancer, mantle cell lymphoma, non-small cell lung cancer, melanoma, colon cancer, esophageal cancer, liposarcoma, multiple myeloma, T-cell leukemia, renal cell carcinoma, gastric cancer, renal cell carcinoma, glioblastoma, hepatocellular carcinoma, gastric cancer, lung cancer, colon cancer or rhabdoid tumor. 10. The method of claim 9 , wherein the cancer is pancreatic cancer, breast cancer, or mantle cell lymphoma. 11. The method of claim 9 , wherein the cancer is a lymphoma. 12. The method of claim 9 , wherein the cancer is rhabdoid tumor.
Assignees
Inventors
Classifications
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Antineoplastic agents · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9867825B2 cover?
- A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).